Sibel HACIOĞLU KABUKÇU, Ali KESKİN, İsmail SARI, Mehmet Hilmi DOĞU

Successful treatment of refractory gastrointestinal bleeding by systemic (oral) ankaferd blood stopper in a patient with glanzmann thrombasthenia

Background: Glanzmann Thrombasthenia (GT) is agenetic platelet dysfunction and a life threatening dis- ease. Ankaferd Blood Stopper (ABS) is a topical he- mostatic agent of herbal origin which has been recentlymade available for clinical use. Its hemostatic effect isindependent from blood clotting factors and occurs as aresult of the aggregation of focal red blood cells by anencapsulated protein web. Case Report: In this paper, a patient with GT is pre- sented in whom 3 months of gastrointestinal bleeding refractory to all medical therapies was controlled with-in a short time of using oral ABS.Conclusion: The difference between this patient andother cases presented in the medical literature is the oraluse of ABS. Thus, this patient may contribute to the medi-cal community in showing the safety and efficacy of sys-temic (oral) ABS in patients with disorders of coagulation.However, there is a need for more patient experiences.

PDF

___

1. Franchini M, Favaloro EJ, Lippi G. Glanzmann thrombasthenia: an update. Clin Chim Acta 2010;41:1-6. [CrossRef]
2. Beyazit Y, Kurt M, Kekilli M, Goker H, Haznedaroglu IC. Eval- uation of hemostatic effects of Ankaferd as an alternative medi- cine. Altern Med Rev 2010;15:329-36.
3. Beyazit Y, Kekilli M, Haznedaroglu IC, Kayacetin E, Basaranoglu M. Ankaferd hemostat in the management of gastrointestinal hem- orrhages. World J Gastroenterol 2011;17:3962-70. [CrossRef]
4. Beyazit Y, Kart T, Kuscu A, Arslan A, Kurt M, Aktas B, et al. Successful management of bleeding after dental procedures with application of blood stopper: a single center prospective trial. J Contemp Dent Pract 2011;12:379-84. [CrossRef]
5. Bakdash S, Lyons JM, Bastacky SI, Pezzone MA, McGee JB, Schoen RE, et al. Management of persistent gastric bleeding in a patient with Glanzmanns thrombasthenia. Am J Hematol 2008;83:411-5. [CrossRef]
6. Bhat S, Yadav SP, Anjan M, Dinand V, Sachdeva A. Recombinant activated factor VII usage in life threatening hemorrhage: a pedi- atric experience. Indian J Pediatr 2011;78:961-8. [CrossRef]
7. Kazancıoğlu HO, Cakır O, Ak G, Zülfkar B. The Effectiveness of a New Hemostatic Agent (Ankaferd Blood Stopper) for the Con- trol of Bleeding following Tooth Extraction in Hemophilia: A Con- trolled Clinical Trial. Turk J Haematol 2013;30:19-24. [CrossRef]
8. Baykul T, Alanoglu EG, Kocer G. Use of Ankaferd Blood Stop- per as a hemostatic agent: a clinical experience. J Contemp Dent Pract 2010;11:88-94.
9. Solak Y, Gaipov A, Ozbek O, Hassan MA, Yeksan M. Massive haematuria successfully managed by intravesical Ankaferd in a haemodialysis patient complicated with disseminated intravas- cular coagulation. BMJ Case Rep 2012;2012.
10. Ozseker B, Shorbagi A, Efe C, Haznedaroglu IC, Bayraktar Y. Control- ling of upper gastrointestinal bleeding associated with severe immune thrombocytopenia via topical adjunctive application of Ankaferd blood stopper. Blood Coagul Fibrinolysis 2012;23:464. [CrossRef]
11. Sonmez M, Baltacioğlu E, Sarac O, Erkut N. The use of Ankaferd blood stopper in a patient with Glanzmanns thrombasthenia with gingival bleeding. Blood Coagul Fibrinolysis 2010;21:382-83. [CrossRef]
12. Leblebisatan G, Bay A, Karakus SC, Kekilli M, Haznedaroglu IC. Topical Ankaferd hemostat application for the management of oral cavity bleedings in children with hemorrhagic diathesis. Blood Coagul Fibrinolysis 2012;23:494-97. [CrossRef]
13. Akbal E, Köklü S, Astarcı HM, Koçak E. Oral high-dose ankaf- erd administration effects on gastrointestinal system. Int J Med Sci 2013;10:451-6. [CrossRef]
14. Kurt M, Oztas E, Kuran S, Onal IK, Kekilli M, Haznedaroglu IC. Tandem oral, rectal, and nasal administrations of Ankaferd Blood Stopper to control profuse bleeding leading to hemody- namic instability. Am J Emerg Med 2009;27:631. [CrossRef]